LRP1B mutation is associated with tumor immune microenvironment and progression-free survival in lung adenocarcinoma treated with immune checkpoint inhibitors

Ziyi He,Wei Feng,Yuxuan Wang,Liang Shi, Yuhui Gong,Yichao Shi,Shiyu Shen,Haitao Huang

Translational lung cancer research（2023）

引用 1|浏览10

暂无评分

摘要

Our study suggests that mutation is associated with higher immune cell infiltration and elevated immune gene expression in TIME and potentially serves as a prognostic biomarker for LUAD patients treated with ICIs.

查看译文

关键词

LPR1B,Lung adenocarcinoma (LUAD),biomarker,immune checkpoint inhibitors (ICIs),tumor immune microenvironment (TIME)

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要